【摘要】：糖尿病是危害人類健康的重大疾病,隨著生活水平的提高、營養(yǎng)結(jié)構(gòu)的改變、交通工具的發(fā)達(dá)、勞動(dòng)強(qiáng)度的降低、再加上環(huán)境惡化、公民社會(huì)心理壓力的漸增,糖尿病已經(jīng)發(fā)展成為一種常見病、多發(fā)病,可能為終身性的慢性疾病。目前已成為嚴(yán)重危害人類健康的公共衛(wèi)生問題。在我國糖尿病發(fā)病率呈增高趨勢(shì),并且出現(xiàn)向低齡化發(fā)展的嚴(yán)重性。因此,防治極為重要。目前,糖尿病造成聽力下降與神經(jīng)性耳聾相近似,病理機(jī)制尚未明確,所有治療的效果非常有限。本文依據(jù)“腎主骨”、“腎開竅于耳”理論,結(jié)合本組患者均有不同程度腎虛證并伴有聽力下降,觀察補(bǔ)腎中藥方結(jié)合辨證療法治療糖尿病聽力臨床研究。目的:糖尿病是危害人類健康的重大疾病,糖尿病所致感音神經(jīng)性耳聾,因其病因尚未明確,所以治療極其困難,根據(jù)糖尿病聽力下降患者均表現(xiàn)程度不同腎虛證,參照“腎主骨”、“腎開竅于耳”理論。本研究觀察補(bǔ)腎中藥方對(duì)糖尿病聽力下降患者療效的影響,為補(bǔ)腎中藥方防治糖尿病聽力下降提供思路與方法。方法:根據(jù)國際標(biāo)準(zhǔn)化組織(ISO)1964年公布的耳聾等級(jí)標(biāo)準(zhǔn),選取2012年10月至2015年11月在河北醫(yī)科大學(xué)附屬邢臺(tái)市人民醫(yī)院內(nèi)分泌科及邢臺(tái)醫(yī)學(xué)高等�？茖W(xué)校第二附屬醫(yī)院中西醫(yī)結(jié)合科308例(416耳)2型糖尿病(NIDDM)伴耳聾患者。屬輕度聾72耳,中度聾120耳,中重度聾132耳,重度聾60耳,深度聾32耳;單側(cè)耳聾236耳,雙側(cè)耳聾180耳;出現(xiàn)突發(fā)性耳聾患者46耳,逐漸發(fā)生所引起耳聾患者370耳。上述患者按病情分組分別進(jìn)行隨機(jī)分為治療組和對(duì)照組:治療組(補(bǔ)腎中藥組)170例(220耳),男73例,女97例,年齡36-69歲,平均50.6歲,病程1-10年,平均4.6年。對(duì)照組(西藥組)138例(196耳),男67例,女71例,年齡34-67歲,平均49.8歲,病程1-9年,平均4.3年。兩組分組經(jīng)齊同性檢驗(yàn)無統(tǒng)計(jì)學(xué)差異(P0.05)。另外兩組均排除的病因包括,藥物中毒性耳聾、腦外傷、噪音性耳聾,以及其它中毒性疾病等病史。診斷標(biāo)準(zhǔn)符合世界衛(wèi)生組織(WHO)確診為NIDDM標(biāo)準(zhǔn)。辯證分型依據(jù)《新藥(中藥)治療糖尿病(消渴病)臨床研究指導(dǎo)原則》。耳聾分級(jí)為國際標(biāo)準(zhǔn)化組織(ISO)1964年公布的耳聾等級(jí)標(biāo)準(zhǔn)。聽力學(xué)療效標(biāo)準(zhǔn):痊愈:治療后聽力逐漸恢復(fù),耳鳴逐漸減至消失,全頻率聽閾曲線漸回升至正常范圍或與健側(cè)相似;顯效:全頻率聽閾曲線較治療前回升超過30d B或進(jìn)入實(shí)用聽區(qū),主觀癥狀明顯好轉(zhuǎn);進(jìn)步:聽閾曲線的多頻率回升15-30d B,主觀癥狀亦好轉(zhuǎn);無效:聽閾曲線的多數(shù)頻率較治療前上升不足15d B,無論主觀癥狀是否好轉(zhuǎn)。治療組170例(220耳)用補(bǔ)腎中藥方結(jié)合辯證論治用藥。對(duì)照組132例糖尿病耳聾患者,用格列本脲片和治療常規(guī)所采用的耳聾藥物。觀察兩組治療前后聽力影響,空腹血糖(FBG)、餐后2h血糖(PBG)、24h尿糖定量,主要見癥改善情況,血小板功能,超氧化物歧化酶(SOD)、過氧化脂質(zhì)(LPO)等變化。結(jié)果:1兩組治療前后聽力比較治療組治療后聽力提高總有效率為57.7%,對(duì)照組為28.5%,兩組比較有明顯差異(P0.05)。2兩組FBG、PBG、24h治療前后變化兩組空腹血糖(FBG)、餐后2h血糖(PBG)、24h尿血糖定量和治療前相比改善明顯(P0.05.P0.01),其中餐后2h血糖(PBG)、24h尿血糖定量治療組療效明顯優(yōu)于對(duì)照組(P0.01),兩組空腹血糖(FBG)無明顯差異(P0.05)。3兩組治療前后主要癥狀改善情況治療組和治療前相比較,在腰膝酸軟、小便量多、易肌善食,消瘦無力等癥狀改善比較明顯,(P0.05.P0.01),而對(duì)照組在上述癥狀改善不明顯。4兩組血小板粘附率、血小板聚集率、超氧化物歧化酶(SOD)、過氧化脂質(zhì)(LPO)治療前后情況治療組治療后血小板粘附率,血小板聚集率,超氧化物歧化酶(SOD),過氧化脂質(zhì)(LPO)有較好改變(P0.05.P0.01),而對(duì)照組除LPO有改變外(P0.05),余三項(xiàng)指標(biāo)均無明顯差異(P0.05)。結(jié)論:1補(bǔ)腎中藥方結(jié)合辨證治療糖尿病聽力下降患者療效確切,未見患者引起副作用癥狀。2補(bǔ)腎中藥方能夠提高糖尿病聽力下降患者聽力、提高超氧化物歧化酶活性,改善糖尿病聽力下降患者主要癥狀,降低血小板聚集、過氧化脂質(zhì)含量,且療效優(yōu)于常規(guī)對(duì)照組治療方法,該研究為中西醫(yī)結(jié)合防治糖尿病耳聾提供較好思路與方法。
[Abstract]:diabetes is a major disease which is harmful to human health, with the improvement of living standard, the change of the nutrition structure, the development of the transportation vehicle, the reduction of the labor intensity, the environment deterioration, the increasing of the psychological pressure of the citizen, the diabetes has developed into a common disease, It may be a life-long, chronic disease. At present, it has become a public health problem which is seriously harmful to human health. The incidence of diabetes in China is increasing, and the severity of the development of diabetes is present. Therefore, the prevention and control is of great importance. At present, the hearing loss caused by diabetes is similar to that of the nerve deafness, the pathological mechanism is not clear, and the effect of all treatments is very limited. According to the "kidney main bone" and "The kidney opens to the ear" theory, in combination with the different degree of kidney deficiency syndrome and the hearing loss of the patients in this group, the clinical study on the treatment of diabetes with the combination of the traditional Chinese medicine prescription and the syndrome differentiation therapy is observed. Objective: Diabetes is a major disease which is harmful to human health. The sensorineural hearing loss due to diabetes is not clear due to its etiology. Therefore, it is extremely difficult to treat, and according to the different degree of kidney deficiency of the patients with impaired hearing, refer to the "kidney main bone" and the "The kidney opens to the ear" theory. The purpose of this study is to observe the effect of the prescription for tonifying the kidney and the effect of the prescription on the patients with impaired hearing, and to provide a train of thought and method for the prevention and treatment of diabetes hearing loss. Method: According to the criteria for the level of deafness published by the International Organization for Standardization (ISO) in 1964, 308 cases (416 ears) of type 2 diabetes mellitus (NIDDM) with deafness were selected from October,2012 to November,2015 at the Second Affiliated Hospital of the People's Hospital of the Affiliated Hospital of Hebei Medical University. Of the patients with mild deafness,72 ears,120 ears with moderate deafness,132 ears with moderate to severe deafness,60 ears with severe deafness,32 ears with deep deafness,236 ears of one-sided deafness and 180 ears of bilateral deafness,46 ears of patients with sudden deafness and 370 ears of patients with sudden deafness. The above-mentioned patients were randomly divided into the treatment group and the control group according to the condition group: the treatment group (the kidney-tonifying traditional Chinese medicine group)170 cases (220 ears), the male 73 cases, the female 97 cases, the age 36-69 years, the average age of 50.6 years, the course of the disease 1-10 years, the average 4.6 years. 138 (196 ears) of the control group (196 ears),67 males and 71 females, aged 34 to 67, had an average of 49.8 years, and the course of the disease ranged from 1 to 9 years, with an average of 4.3 years. There was no statistical difference between the two groups (P0.05). The other two groups are excluded from the medical history of drug-induced deafness, brain trauma, noise deafness, and other toxic diseases. The diagnostic criteria were met by the World Health Organization (WHO) as the NIDDM standard. The dialectical type is based on the guiding principle of the clinical study of the treatment of diabetes (diabetes) by the new drug (traditional Chinese medicine). Deafness classification is the standard of hearing loss published by the International Organization for Standardization (ISO) in 1964. The results are as follows: after the treatment, the hearing is gradually restored, the tinnitus is gradually reduced, the full-frequency auditory threshold curve is gradually recovered to the normal range or similar to the healthy side, and the whole-frequency auditory threshold curve is more than 30 days before the treatment, or enters the practical auditory zone, and the subjective symptom is improved; Progress: The multi-frequency recovery of the auditory threshold curve is up to 15-30 d B, and the subjective symptoms are also improved; the majority of the frequency of the auditory threshold curve is less than 15 d B before the treatment, whether the subjective symptom is improved or not. In the treatment group,170 cases (220 ears) were treated with the traditional Chinese medicine for tonifying the kidney. In the control group,132 patients with diabetes and deafness were treated with gliclazide tablets and the treatment of the conventional deafness drugs. The effects of two groups of pre-and post-treatment hearing, fasting blood glucose (FBG),2-hour postprandial blood glucose (PBG) and 24-hour urine glucose were observed, and the changes of blood platelet function, superoxide dismutase (SOD) and lipid peroxide (LPO) were observed. Results: The total effective rate of the two groups was 57.7% after treatment and 28.5% in the control group, and there was a significant difference between the two groups (P0.05). The two groups of FBG, PBG, and 24h were treated with two groups of fasting blood glucose (FBG) before and after treatment. After 2 h postprandial blood glucose (PBG) and 24 h urine glucose level and pre-treatment, the blood glucose (PBG) and 24h urine glucose were significantly better than those in the control group (P 0.01). There was no significant difference between the two groups of fasting blood glucose (FBG) (P0.05). in that control group, the platelet adhesion rate, the platelet aggregation rate, the superoxide dismutase (SOD), the platelet aggregation rate, the platelet aggregation rate, the superoxide dismutase (SOD), The lipid peroxide (LPO) of the control group was better than that of the control group (P0.05). Conclusion:1. The traditional Chinese medicine prescription can improve the hearing of the patients with impaired hearing, improve the activity of the superoxide dismutase and improve the main symptoms of the patients with impaired hearing. In ord to reduce that aggregation of the platelet and the content of the lipid peroxide, and the curative effect is superior to that of the conventional control group, the study provides a good idea and a method for preventing and treating the diabetic deafness by combination of the traditional Chinese and western medicine.
【學(xué)位授予單位】：河北醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類號(hào)】：R276.1;R259

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 ;糖尿病[J];國外科技資料目錄.醫(yī)藥衛(wèi)生;1998年10期

2 ;糖尿病[J];國外科技資料目錄.醫(yī)藥衛(wèi)生;1998年01期

3 仝小林;;糖尿病9問(上)[J];藥物與人;2007年03期

4 王秋月,劉國良;生活習(xí)慣與糖尿病[J];醫(yī)師進(jìn)修雜志;2000年09期

5 陳廣耀;抗糖尿病中藥開發(fā)前景展望[J];中國新藥雜志;2000年07期

6 太田康晴,莊祥云;糖尿病[J];日本醫(yī)學(xué)介紹;2000年08期

7 ;糖尿病[J];國外科技資料目錄.醫(yī)藥衛(wèi)生;2000年06期

8 ;糖尿病[J];國外科技資料目錄.醫(yī)藥衛(wèi)生;2000年08期

9 ;糖尿病[J];國外科技資料目錄.醫(yī)藥衛(wèi)生;2000年11期

10 林蘭;倪青;董彥敏;;糖尿病中西醫(yī)結(jié)合研究的思路與方法[J];醫(yī)學(xué)研究通訊;2001年09期

相關(guān)會(huì)議論文 前10條

1 吳東方;莊躍宏;陳秀芳;趙麗娜;楊曉東;唐茂林;;胰島素依賴型糖尿病對(duì)大鼠隨意皮瓣存活能力的影響[A];中國解剖學(xué)會(huì)2012年年會(huì)論文文摘匯編[C];2012年

2 崔瑾;韓姣姣;李鳳翱;李鳳翱;湯紹芳;劉萍;邱明才;張鵬;;1,25-二羥維生素D3對(duì)糖尿病大鼠肺臟病變的保護(hù)作用[A];中華醫(yī)學(xué)會(huì)第十二次全國內(nèi)分泌學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2013年

3 鄭濱珠;袁鳳山;楊潤橋;;自體干細(xì)胞激活療法治療糖尿病大鼠過程中血細(xì)胞及生化改變[A];中華醫(yī)學(xué)會(huì)第十二次全國內(nèi)分泌學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2013年

4 劉銅華;呂仁和;高彥彬;;中醫(yī)藥防治糖尿病及并發(fā)癥的作用途徑[A];糖尿�。ㄏ什。┲嗅t(yī)診治薈萃——全國第五次中醫(yī)糖尿病學(xué)術(shù)大會(huì)論文集[C];1999年

5 石鳳英;王堯;;靈芝對(duì)糖尿病大鼠腎臟形態(tài)學(xué)及微量白蛋白尿的作用[A];中國康復(fù)醫(yī)學(xué)會(huì)第三次康復(fù)治療學(xué)術(shù)大會(huì)論文匯編[C];2002年

6 陳名道;李榮英;邵莉;;糖尿病飲食治療的若干進(jìn)展[A];中國營養(yǎng)學(xué)會(huì)第九次全國營養(yǎng)學(xué)術(shù)會(huì)議論文摘要匯編[C];2004年

7 仝小林;李洪皎;;糖絡(luò)并重治療2型糖尿病[A];第九次全國中醫(yī)糖尿病學(xué)術(shù)大會(huì)論文匯編[C];2006年

8 李筱榮;李艷;劉巨平;袁佳琴;;糖尿病大鼠血—視網(wǎng)膜屏障損傷的實(shí)驗(yàn)研究[A];中華醫(yī)學(xué)會(huì)第十二屆全國眼科學(xué)術(shù)大會(huì)論文匯編[C];2007年

9 楊毅;陳江華;王晶晶;秦嶺;;雷帕霉素對(duì)糖尿病大鼠腎臟組織增殖和肥大的抑制作用[A];2007年浙滬兩地腎臟病學(xué)術(shù)年會(huì)資料匯編[C];2007年

10 祁少海;劉坡;舒斌;謝舉臨;徐盈斌;黃勇;毛任翔;劉旭盛;;不同深度糖尿病大鼠燙傷模型的制備[A];第八屆全國燒傷外科學(xué)年會(huì)論文匯編[C];2007年

相關(guān)重要報(bào)紙文章 前10條

1 郭賽珊　梁曉春 潘明政;中西醫(yī)結(jié)合治療糖尿病慢性并發(fā)癥可顯著改善癥狀[N];中國中醫(yī)藥報(bào);2007年

2 本報(bào)記者 王樂羊;中西醫(yī)結(jié)合防治糖尿病大有可為[N];中國中醫(yī)藥報(bào);2002年

3 北京協(xié)和醫(yī)院 梁曉春;對(duì)中醫(yī)治糖尿病并發(fā)癥研究的思考[N];中國中醫(yī)藥報(bào);2011年

4 劉燕玲;肥胖是糖尿病的源頭[N];健康報(bào);2006年

5 仝小林;糖尿病慢性并發(fā)癥論治[N];中國中醫(yī)藥報(bào);2003年

6 汪敏;糖尿病皮膚易損元兇找到[N];衛(wèi)生與生活報(bào);2003年

7 林蘭;中西醫(yī)結(jié)合治療糖尿病的前景[N];中國中醫(yī)藥報(bào);2007年

8 北京協(xié)和醫(yī)院中醫(yī)科主任 梁曉春;糖尿病周圍神經(jīng)病變的中西醫(yī)治療進(jìn)展[N];中國醫(yī)藥報(bào);2009年

9 本報(bào)記者 劉艷芳;糖尿病干預(yù)不能忽視抗氧化[N];中國食品報(bào);2012年

10 譚小月;糖尿病與腎病關(guān)系研究的新進(jìn)展[N];中國中醫(yī)藥報(bào);2004年

相關(guān)博士學(xué)位論文 前10條

1 馮偉偉;蘋果酸鉻對(duì)2型糖尿病大鼠的降血糖活性、作用機(jī)制及安全性初探[D];江蘇大學(xué);2015年

2 劉宇;糖尿病來源的骨髓間充質(zhì)干細(xì)胞治療心肌梗死的相關(guān)研究[D];第四軍醫(yī)大學(xué);2015年

3 李維辛;GLP-1受體激動(dòng)劑治療糖尿病的循證評(píng)價(jià)和對(duì)糖尿病大鼠胃動(dòng)力影響的機(jī)制研究[D];蘭州大學(xué);2012年

4 田麗;糖尿病周圍神經(jīng)病運(yùn)動(dòng)纖維的早期評(píng)價(jià)[D];天津醫(yī)科大學(xué);2014年

5 柳忠豪;糖尿病對(duì)口腔種植體骨整合影響的作用機(jī)制研究[D];山東大學(xué);2015年

6 李波;飽和富氫液對(duì)糖尿病神經(jīng)病變的保護(hù)作用及機(jī)制研究[D];天津醫(yī)科大學(xué);2015年

7 米佳;Vaspin調(diào)控糖尿病炎癥通路及苦酸通調(diào)法的干預(yù)機(jī)制研究[D];長(zhǎng)春中醫(yī)藥大學(xué);2015年

8 林宣佑;從SCAP/SREBP脂代謝信號(hào)轉(zhuǎn)導(dǎo)途徑探討苦酸通調(diào)方調(diào)控2型糖尿病胰島素抵抗的作用機(jī)制[D];長(zhǎng)春中醫(yī)藥大學(xué);2015年

9 齊月;木丹顆粒治療痛性糖尿病周圍神經(jīng)病變的實(shí)驗(yàn)研究[D];遼寧中醫(yī)藥大學(xué);2015年

10 王云;糖基化終末產(chǎn)物介導(dǎo)的平滑肌病變?cè)谔悄虿〗Y(jié)腸動(dòng)力障礙中的作用研究[D];南京醫(yī)科大學(xué);2013年

相關(guān)碩士學(xué)位論文 前10條

1 田寶明;低血糖指數(shù)掛面的研制及其對(duì)糖尿病大鼠糖脂代謝影響的研究[D];西南大學(xué);2015年

2 黃瓊;姜黃素對(duì)糖尿病大鼠肺組織損傷的保護(hù)作用及其可能機(jī)制[D];湖北科技學(xué)院;2015年

3 褚淑蕾;PI3k-Akt信號(hào)通路在2型糖尿病大鼠易發(fā)心房顫動(dòng)中的介導(dǎo)作用[D];福建醫(yī)科大學(xué);2015年

4 石鷹;二膦酸鹽對(duì)糖尿病大鼠下頜骨骨折愈合影響的實(shí)驗(yàn)研究[D];河北聯(lián)合大學(xué);2014年

5 鄭嫦;CNP對(duì)Ach引起的糖尿病大鼠胃平滑肌收縮增強(qiáng)的影響及IGF-1的干預(yù)效應(yīng)[D];延邊大學(xué);2015年

6 李寧;益氣養(yǎng)陰活血方對(duì)糖尿病大鼠大血管NF-κB表達(dá)的影響[D];河北醫(yī)科大學(xué);2015年

7 王婉秋;辛伐他汀對(duì)2型糖尿病動(dòng)脈硬化大鼠血漿VEGF、TGF-β1及CTRP3水平的影響研究[D];石河子大學(xué);2015年

8 宋倩;2型糖尿病患者血清TLR-4水平與骨密度及影響因素關(guān)系研究[D];河北醫(yī)科大學(xué);2015年

9 王麗霞;TLR4及相關(guān)炎癥因子在糖尿病大鼠心臟、肝臟和腎臟中的表達(dá)[D];河北醫(yī)科大學(xué);2015年

10 孫雪培;極長(zhǎng)鏈脂肪酸與2型糖尿病大鼠腦Aβ生成的關(guān)系研究[D];河北醫(yī)科大學(xué);2015年

，

本文編號(hào)：2447179